Compare Global X SuperDividend ETF (SDIV) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X SuperDividend ETF vs Summit Therapeutics Inc — how do they compare? Global X SuperDividend ETF trades at $23.94 (market cap $1.17B), while Summit Therapeutics Inc trades at $17.34 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 11.7× Global X SuperDividend ETF's market cap, and Global X SuperDividend ETF is more actively traded (387,692 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold Global X SuperDividend ETF for 47 Days and Summit Therapeutics Inc for 16 Days on average.
| SDIV | SMMT | |
|---|---|---|
Market Cap | $1.17B | $13.71B |
Volume | 387,692 | 6,173,057 |
Sector | Broad Market / Factor | Health |
52-Week High | $26.34 | $26.38 |
52-Week Low | $22.90 | $12.43 |
Typical Hold Time | 47 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SDIV trades at $23.58, down 0.55% with a bearish technical signal from moving averages. The ETF maintains an 8%+ dividend yield but faces scrutiny over principal erosion, having lost 66% since inception. Recent institutional buying by Ameritas Advisory contrasts with negative media coverage questioning sustainability of high yields amid capital depreciation.
Outlook remains challenged by structural underperformance versus benchmarks. The high yield attracts income seekers but masks negative growth and volatility risks. Investment case hinges on yield sustainability versus capital preservation, with analyst sentiment cautious given persistent track record of value destruction.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
